Moderna is showcasing its R&D pipeline to investors today, but the headline news is a decision to cut its R&D spend by a massive $1.1 billion a year from 2027, reversing years of gr
The BioIndustry Association (BIA) has asked new UK Chancellor Rachel Reeves for a nuanced approach to R&D tax credits in the upcoming budget, saying that the life sciences should not be
The sweeping changes introduced by new BioMarin chief executive Alexander Hardy continue apace, with a second round of layoffs that will cut another 225 positions from its total headcount.
Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for startin
Bayer has joined its peers among European drugmakers with a hike in pharma forecasts for the year, as it recorded a rise in group sales, but lower profits for the second quarter.
A proposal by 23andMe founder and chief executive Anne Wojcicki to take the genetic testing company private has been rejected by a special committee of the board of directors.
UK Prime Minister Keir Starmer has promised the biggest 'reimagining' of the NHS in its history but stressed there would be no more funding without sweeping reforms.
The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpo